Background: Streptococcus mutans is a leading causative agent of dental caries and exerts pathogenicity by forming biofilms. Dental caries continues to be a significant public health issue worldwide, affecting an estimated 2.5 billion people, showing a 14.6% increase over the past decade. Herein, the antibacterial potential of Chlorophyllin extracted from Spinacia oleracea was evaluated against biofilm-forming S. mutans via in vitro and in silico studies. Methodology: The antimicrobial activity of chlorophyllin extract against S. mutans isolates was tested using the agar well diffusion method. Chlorophyllin extract was also tested against biofilm-forming isolates of S. mutans. Chlorophyllin was docked with the antigen I/II (AgI/II) protein of S. mutans to evaluate its antimicrobial mechanism. The chemical structure and canonical SMILES format of Chlorophyllin were obtained from PubChem. Additionally, adsorption, distribution, metabolism, excretion, and toxicity (ADMET) analyses of Chlorophyllin were performed using ADMETlab 2.0 to assess its pharmacokinetic properties. Results: An agar well diffusion assay revealed that all S. mutans isolates were susceptible to Chlorophyllin extract and showed a variety of inhibition zones ranging from 32 to 41 mm. Chlorophyllin reduces the biofilm strength of four isolates from strong to moderate and six from strong to weak. The antibiofilm potential of Chlorophyllin was measured by a reduction in the number of functional groups observed in the Fourier Transform Infrared Spectrometer (FTIR) spectra of the extracellular polymeric substance (EPS) samples. Chlorophyllin showed binding with AgI/II proteins of S. mutans, which are involved in adherence to the tooth surface and initiating biofilm formation. The ADMET analysis revealed that the safety of Chlorophyllin exhibited favorable pharmacokinetic properties. Conclusions: Chlorophyllin stands out as a promising antibacterial and antibiofilm agent against biofilm-forming S. mutans, and its safety profile highlights its potential suitability for further investigation as a therapeutic agent.

This article explores the potential of phytochemicals as immunomodulatory agents in cancer therapy, bridging the gap between traditional plant-based medicine and modern oncological treatments. Phytochemicals, including flavonoids, alkaloids, terpenoids, and polyphenols, have demonstrated significant immunomodulatory properties that can enhance immune system function and promote anti-tumor responses. These bioactive compounds work by modulating key signaling pathways, including immune cell activation, cytokine production, and tumor microenvironment interactions. Despite their promising therapeutic potential, challenges remain in optimizing their bioavailability and therapeutic efficacy. This review highlights the latest advances in the use of phytochemicals for cancer immunotherapy, discussing their mechanisms of action, clinical applications, and the need for further research to fully harness their potential in combination with existing cancer treatments. Integrating these natural compounds into modern cancer therapy could provide novel, effective and less toxic treatment options for cancer patients.